RGAL Catches the Spotlight: Official Listing on April 25
High publicity on the coming listing of RGAL.
Taipei, Taiwan, April 23, 2012 - Rotam Global AgroSciences Limited (RGAL)’s Taiwan listing project is at its final stage following the Investor Conference held at the end of last month. RGAL has scheduled its official listing F – 龍燈(4141) in the Taiwan Stock Exchange on April 25th, 2012.
There has been a lot of interest from the press in RGAL and its founder. Reports and interviews of Chairman, Mr Mark Lu, have appeared in a wide range of economic journals and in the financial media. In additional to the unique nature of its global business model, its creative strategic approach and its strong global Brands, RGAL’s good future prospects have developed a wide interest among the financial sector and investors in Taiwan.
Mr Mark Lu, Chairman of RGAL.
Apart from the stable and substantial profit of RGAL, Canadian Taiwanese, Chairman Lu’s deep roots in Taiwan and the Life Science Sector are fundamental to the success of the company. Chairman Lu comes from a medical family, his father is one of the founders of Chi Mei Medical Center and the Medicine Shopper’s Franchise. Family operated Swiss Pharmaceutical Co., Ltd., is one of the top ten pharmaceutical manufacturers in Taiwan with over 50 years of history. The related active pharmaceutical ingredient (API) trading enterprises have over 60 year of history and still supply one-fourth of the total APIs in Taiwan as well as professional drug development assistance and technical service to hundreds of pharmaceutical manufacturers throughout the country. Chairman Lu is also the founder, former general manager and present vice Chairman of Kunshan Rotam Reddy Pharmaceuticals Limited (KRRP), which is a joint venture in China between the Rotam Group and Dr. Reddy’s Laboratories Ltd. of India which is one of the top ten pharmaceutical post patent manufacturers in the world. Under the family influence and his solid life science background, Chairman Lu has developed a business model which focuses more innovation across the scope of crop protection rather than tradition pesticides. This is done through a focused and continuous investment in Research, Development and Enhancement of Products; Original Toxicological, Eco-toxicology and Environmental Data generation; Leveraging the Mainland’s advantages in proximity to raw materials and joint venture packaging excellence. During the years, he has established a strong sales and marketing network of carrying Rotam brands to users in over 60 agricultural countries. RGAL is the only global crop protection company to have centralized Greater China production hub to supply the crop protection products globally which brings the benefits of continuity in production, allowing a full utilization of manufacturing capacity to meet seasonal demands across both the Northern and Southern hemispheres. Moreover, in order to enhance the development of its own herbicide products, RGAL incorporates crop protection products with a program of seed gene and trait development using non-transgenic technology whilst bringing benefit to farmers in key crops. The Company decided to have its Initial Public Offering in Taiwan and aims to provide higher efficacy and safer products to farmers in the home country.
Under the leadership of Chairman Lu, it is expected that RGAL’s official listing would open a new era for both investors and the industry.
Notes to Editors:
RGAL (www.rotam.com) is a fast-growing international biotechnology organization operating mainly in crop protection products. Through its worldwide multidirectional integrated research and development, registration, manufacturing, marketing and technical support, Rotam is operating in over 60 countries including major agricultural markets like the European Union, Brazil and the North American Free Trade Area.
For more information contact Rotam at email@example.com.